Effect of high dose N-acetyl cysteine supplementation on markers of oxidative stress and insulin resistance in non-diabetic patients with metabolic dysfunction associated steatotic liver disease: a randomized controlled trial

Hepatology

Vitamin E dosing study (VEDS) in patients with metabolic dysfunction-associated steatotic liver disease with elevated aminotransferases: A multicenter, randomized, placebo-controlled trial

Hepatology

Dasarathy S, Mitchell EP, Wilson LA, Neuschwander-Tetri BA, Chalasani N, Clark JM, Diehl AM, Hameed B, Loomba R, Yuan L, Kowdley KV, Sanyal AJ, NASH Clinical Research Network

doi: 10.1097/HEP.0000000000001797

Hepatology

Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis

Lancet Gastroenterol Hepatol

Celsa C, Pennisi G, Tulone A, Ciancimino G, Vaccaro M, Pecorella F, Di Maria G, Enea M, Midiri F, Mantovani A, Targher G, Krag A, Rinella ME, Cammà C, Petta S

doi: 10.1016/S2468-1253(25)00188-8

Hepatology

Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study

Lancet Gastroenterol Hepatol

Lazarus JV, Agirre-Garrido L, White TM, Arora AK, Manolas MI, Diaz LA, Arab JP, Zelber-Sagi S, Alkhouri N, Spearman CW, Schattenberg JM, Kondili LA, Carrieri P, Lofton HF, Jaisinghani P, Kumar S, Duseja A, El-Kassas M, Takahasi H, Shawcross DL, Stine JG, Villota-Rivas M, Miralles-Sanchez JE, Pannain S, Brennan PN, MASLD/MASH Collaborators

doi: 10.1016/S2468-1253(25)00300-0

Hepatology

Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease

J Gastroenterol Hepatol

Hsieh ML, Su TH, Lin YC, Chen YY, Tung CF, Huang LS, Wu CH, Peng YC, Hsieh VC

doi: 10.1111/jgh.70259

Further Publications

Clinical Care Pathway for the Risk Stratification and Management of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

Gastroenterology

Kanwal F, Bril F, Wai-Sun Wong V, Adams LA, Pfotenhauer K, Skolnik N, Wright EE Jr, Eckel RH, Noureddin M, Loomba R, Allen AM, Bansal MB, Godwin KM, El-Serag HB, Shubrook JH

doi: 10.1053/j.gastro.2026.01.047

Helicobacter Pylori

Effects of Helicobacter pylori Eradication on the Risk and Clinical Parameters of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis

Helicobacter

Li X, Tao Y, Li H, Mai L, He X, Yan J, Yang X

doi: 10.1111/hel.70092

HepatitisHepatology

Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease

Gut

Chang YP, Chen YC, Cheng PN, Fang YJ, Chen CY, Kao WY, Lin CL, Yang SS, Shih YL, Peng CY, Lee FJ, Tsai MC, Huang SC, Su TH, Tseng TC, Liu CJ, Chen PJ, Kao JH, Liu CH

doi: 10.1136/gutjnl-2025-337275

Further Publications

Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025)

BMC Gastroenterol

Hamood M, Al-Salehi MA, Hussein AF, Naji KM, Rawal R

doi: 10.1186/s12876-026-05160-2

Hepatology

Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial

Lancet Gastroenterol Hepatol

Loomba R, George J, Castera L, Francque S, Lawitz E, Shoeb A, Clausen JO, Andersen B, Larsen AB, Gluud LL

doi: 10.1016/S2468-1253(26)00123-8

Related content

Vitamin E dosing study (VEDS) in patients with metabolic dysfunction-associated steatotic liver disease with elevated aminotransferases: A multicenter, randomized, placebo-controlled trial

Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis

Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study

Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease

Clinical Care Pathway for the Risk Stratification and Management of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

Effects of Helicobacter pylori Eradication on the Risk and Clinical Parameters of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis

Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease

Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025)

Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial